Higher level of actively circulating lymphocytes = greater response rate to DCVax-L? Indubitably as long as there is a check down on Tregs by sufficient cytokine release or CI.
It's not only the reintensification of dosing in this trial upon crossover from the treatment arm upon recurrence, it is simply the fact they continue DCVax-L therapy at all after recurrence. My suspicion is that will also help the proneurals -- JMO. A silver lining?
News 
Market Data 
Discover 
AI
